KLB and hepatocellular carcinoma: The HCC lines HCC13-0109, HCC26-0808A, and HCC17-0211, which express FGFR1-4 and Klotho β but not FGF19, are sensitive to infigratinib (pan-FGFR inhibitor) but not FGF401.